Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both
Journal of the American Society of Nephrology · 2026-04 · 37 (4) · 764-776
DOI: 10.1681/asn.0000000928 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 06.11.2025. Verfasst von Amy Mottl und 13 weiteren Autor:innen. Beteiligte Einrichtung: University of North Carolina School of Medicine, Chapel Hill, North Carolina. Hauptthemen laut MEDLINE: Glucosides, Benzhydryl Compounds, Albuminuria, Creatinine. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer.
Abstract (Originalsprache)
Key Points We assessed whether baseline urine albumin-creatinine ratio (UACR) and eGFR modify treatment effects on UACR reduction and safety in the CONFIDENCE trial. Higher baseline eGFR or UACR, age, female sex, and atherosclerotic cardiovascular disease were associated with greater albuminuria lowering at 6 months (180 days). Treatment effects on efficacy and safety were consistent, with no significant heterogeneity across baseline UACR or eGFR groups.
Background
In the CONFIDENCE trial, simultaneous initiation of finerenone (10 or 20 mg) and empagliflozin (10 mg) was superior to either monotherapy in reducing albuminuria at 180 days in participants with type 2 diabetes and CKD. In this analysis, we evaluated whether baseline urine albumin-creatinine ratio (UACR) and eGFR were associated with the magnitude of UACR reduction, and whether baseline UACR and eGFR modify the effect of combination treatment.
Methods
In this post hoc analysis of the CONFIDENCE trial ( n =796), linear mixed-effects models were used to evaluate the effects of baseline UACR and eGFR on the change in UACR from baseline using subgroups on the basis of clinically relevant thresholds of UACR (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of North Carolina School of Medicine, Chapel Hill, North Carolina.
- Bayer Healthcare Inc., Whippany, New Jersey.
- Duke University School of Medicine, Durham, North Carolina.
- University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.
- KfH Kidney Centre Munich and Friedrich Alexander University, Erlangen, Germany.
- Division of Endocrinology, Metabolism and Lipid Research, Washington University in St. Louis, St. Louis, Missouri.
ORCID-Profile: Amy Mottl, Charlie Scott, Jennifer B Green, Hiddo J L Heerspink, Johannes F E Mann, Janet B McGill, Masaomi Nangaku, Julio Rosenstock, Peter Rossing, Muthiah Vaduganathan, Rajiv Agarwal
Förderung
- Bayer
Zitieren
APA
Mottl, A., Scott, C., Green, J. B., Heerspink, H. J. L., Mann, J. F. E., McGill, J. B., Nangaku, M., Rosenstock, J., Rossing, P., Li, L., Li, N., Vaduganathan, M., Agarwal, R., & CONFIDENCE Trial Investigators (2026). Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both. Journal of the American Society of Nephrology, 37(4), 764-776. https://doi.org/10.1681/asn.0000000928
Vancouver
Mottl A, Scott C, Green JB, Heerspink HJL, Mann JFE, McGill JB, et al. Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both. Journal of the American Society of Nephrology. 2026;37(4):764-776. doi:10.1681/asn.0000000928
BibTeX
@article{Mottl2026,
author = {Mottl, Amy and Scott, Charlie and Green, Jennifer B and Heerspink, Hiddo J L and Mann, Johannes F E and McGill, Janet B and Nangaku, Masaomi and Rosenstock, Julio and Rossing, Peter and Li, Li and Li, Na and Vaduganathan, Muthiah and Agarwal, Rajiv and CONFIDENCE Trial Investigators, CONFIDENCE Trial Investigators},
title = {Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both},
journal = {Journal of the American Society of Nephrology},
year = {2026},
volume = {37},
number = {4},
pages = {764--776},
doi = {10.1681/asn.0000000928}
}
EUVIMED